Skip to main content

Optimizing Pharmacotherapy in Older Patients: An Interdisciplinary Approach: Chronic Kidney Disease

  • Chapter
  • First Online:
Optimizing Pharmacotherapy in Older Patients

Part of the book series: Practical Issues in Geriatrics ((PIG))

  • 585 Accesses

Abstract

Optimizing pharmacological treatments among older people with chronic kidney disease (CKD) is by no means an easy task. It may be very difficult to distinguish changes in kidney function related to aging from clinically relevant CKD. Additionally, among older people, CKD is usually observed in the context of complex multimorbidity profiles which may conceal its clinical presentation and delay diagnosis. Guidelines not always provide age-specific recommendations for treating CKD and related disorders, and there is substantial evidence suggesting that target of treatments should carefully adapted to the older population. Additionally, CKD is known to increase the risk of nephrotoxicity. Taking into account patient- and drug-related factors, as well as avoiding potentially dangerous interactions and reducing inappropriate prescribing, may be useful to prevent nephrotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.

    Google Scholar 

  2. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 Suppl 1):A7, e1–420.

    PubMed  Google Scholar 

  3. Aucella F, Corsonello A, Leosco D, Brunori G, Gesualdo L, Antonelli-Incalzi R. Beyond chronic kidney disease: the diagnosis of Renal Disease in the Elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG). J Nephrol. 2019;32(2):165–76.

    PubMed  PubMed Central  Google Scholar 

  4. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.

    PubMed  Google Scholar 

  5. Glassock RJ. Con: Thresholds to define chronic kidney disease should not be age dependent. Nephrol Dial Transplant. 2014;29(4):774–9; discussion 9–82.

    PubMed  Google Scholar 

  6. Glassock R, Delanaye P, El Nahas M. An age-calibrated classification of chronic kidney disease. JAMA. 2015;314(6):559–60.

    CAS  PubMed  Google Scholar 

  7. Formiga F, Ferrer A, Sanz H, Marengoni A, Alburquerque J, Pujol R, et al. Patterns of comorbidity and multimorbidity in the oldest old: the Octabaix study. Eur J Intern Med. 2013;24(1):40–4.

    PubMed  Google Scholar 

  8. Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of multimorbidity in middle-aged and older adults: an analysis of the UK Biobank data. Mayo Clin Proc. 2018;93(7):857–66.

    PubMed  Google Scholar 

  9. Corsonello A, Fabbietti P, Formiga F, Moreno-Gonzalez R, Tap L, Mattace-Raso F, et al. Chronic kidney disease in the context of multimorbidity patterns: the role of physical performance : The screening for CKD among older people across Europe (SCOPE) study. BMC Geriatr. 2020;20(Suppl 1):350.

    PubMed  PubMed Central  Google Scholar 

  10. Corsonello A, Pedone C, Corica F, Mussi C, Carbonin P, Antonelli Incalzi R, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med. 2005;165(7):790–5.

    PubMed  Google Scholar 

  11. Incalzi RA, Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V, et al. Chronic renal failure: a neglected comorbidity of COPD. Chest. 2010;137(4):831–7.

    PubMed  Google Scholar 

  12. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011;79(12):1361–9.

    PubMed  PubMed Central  Google Scholar 

  13. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20(1):223–8.

    PubMed  PubMed Central  Google Scholar 

  14. Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE 2nd, Perkins RM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 2012;81(5):477–85.

    PubMed  Google Scholar 

  15. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.

    PubMed  Google Scholar 

  16. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120–31.

    PubMed  Google Scholar 

  17. Bakris G, Ali W, Parati G. ACC/AHA versus ESC/ESH on hypertension guidelines: JACC guideline comparison. J Am Coll Cardiol. 2019;73(23):3018–26.

    PubMed  Google Scholar 

  18. Verbeke F, Lindley E, Van Bortel L, Vanholder R, London G, Cochat P, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant. 2014;29(3):490–6.

    PubMed  Google Scholar 

  19. Cheung A, Chang TI, Cushman W, Furth S, Hou FF, Ix JH, et al. KDIGO (Kidney Disease: Improving Global Outcomes) guideline update on the management of blood pressure in chronic kidney disease: what’s new and what’s different from other guidelines. Hypertension. 2021;78(suppl_1):A52. -A.

    Google Scholar 

  20. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021–104.

    PubMed  Google Scholar 

  21. Franklin SS, Gokhale SS, Chow VH, Larson MG, Levy D, Vasan RS, et al. Does low diastolic blood pressure contribute to the risk of recurrent hypertensive cardiovascular disease events? Hypertension. 2015;65(2):299–305.

    CAS  PubMed  Google Scholar 

  22. van Bemmel T, Woittiez K, Blauw GJ, van der Sman-de BF, Dekker FW, Westendorp RG, et al. Prospective study of the effect of blood pressure on renal function in old age: the Leiden 85-Plus Study. J Am Soc Nephrol. 2006;17(9):2561–6.

    PubMed  Google Scholar 

  23. Weiss JW, Johnson ES, Petrik A, Smith DH, Yang X, Thorp ML. Systolic blood pressure and mortality among older community-dwelling adults with CKD. Am J Kidney Dis. 2010;56(6):1062–71.

    PubMed  PubMed Central  Google Scholar 

  24. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. 2021;99(3):S1–S87.

    Google Scholar 

  25. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62(2):201–13.

    PubMed  PubMed Central  Google Scholar 

  26. Page MR, The JNC. 8 hypertension guidelines: an in-depth guide. Am J Manag Care. 2014;20(1):E8.

    PubMed  Google Scholar 

  27. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. New Engl J Med. 2021;385(27):2507–19.

    CAS  PubMed  Google Scholar 

  28. Douros A, Ebert N, Jakob O, Martus P, Kreutz R, Schaeffner E. Estimating kidney function and use of oral antidiabetic drugs in elderly. Fundam Clin Pharmacol. 2015;29(3):321–8.

    CAS  PubMed  Google Scholar 

  29. de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4):S1–S115.

    Google Scholar 

  30. de Boer IH, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Khunti K, et al. Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int. 98:2020, 839–848.

    Google Scholar 

  31. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75.

    PubMed  PubMed Central  Google Scholar 

  32. Navaneethan SD, Zoungas S, Caramori ML, Chan JC, Heerspink HJ, Hurst C, et al. Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline. 2021;174(3):385–94.

    Google Scholar 

  33. KDOQI clinical practice guideline for diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60(5):850–86.

    Google Scholar 

  34. Wang W, Zhou X, Kwong JSW, Li L, Li Y, Sun X. Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. Sci Rep. 2017;7(1):1717.

    PubMed  PubMed Central  Google Scholar 

  35. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2021;372:m4573.

    PubMed  Google Scholar 

  36. Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34(6):1247–58 e22.

    CAS  PubMed  Google Scholar 

  37. Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine. 2014;46(3):406–19.

    CAS  PubMed  Google Scholar 

  38. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463–76.

    PubMed  PubMed Central  Google Scholar 

  39. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

    CAS  PubMed  Google Scholar 

  40. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–17.

    CAS  PubMed  Google Scholar 

  41. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

    CAS  PubMed  Google Scholar 

  42. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

    CAS  PubMed  Google Scholar 

  43. Sehgal V, Bajwa SJ, Sehgal R, Consalvo JA. Management of diabetes in the elderly with canagliflozin: a newer hypoglycemic drug on the horizon. J Pharmacol Pharmacother. 2014;5(4):227–31.

    PubMed  PubMed Central  Google Scholar 

  44. Mende CW. Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape. Adv Ther. 2022;39(1):148–64.

    CAS  PubMed  Google Scholar 

  45. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol. 2013;9(5):529–50.

    CAS  PubMed  Google Scholar 

  46. Kiss I, Arold G, Roepstorff C, Bottcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175–83.

    CAS  PubMed  Google Scholar 

  47. Murton M, Goff-Leggett D, Bobrowska A, Garcia Sanchez JJ, James G, Wittbrodt E, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Adv Ther. 2021;38(1):180–200.

    PubMed  Google Scholar 

  48. Verma V, Kant R, Sunnoqrot N, Gambert SR. Proteinuria in the elderly: evaluation and management. Int Urol Nephrol. 2012;44(6):1745–51.

    CAS  PubMed  Google Scholar 

  49. Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care. 2006;29(10):2210–7.

    CAS  PubMed  Google Scholar 

  50. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.

    CAS  PubMed  Google Scholar 

  51. Ren F, Tang L, Cai Y, Yuan X, Huang W, Luo L, et al. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy. Ren Fail. 2015;37(4):548–61.

    CAS  PubMed  Google Scholar 

  52. Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–15.

    Google Scholar 

  53. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.

    CAS  PubMed  Google Scholar 

  54. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.

    CAS  PubMed  Google Scholar 

  55. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–407.

    CAS  PubMed  Google Scholar 

  57. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e143.

    PubMed  Google Scholar 

  58. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37–45.

    CAS  PubMed  Google Scholar 

  59. Nemerovski CW, Lekura J, Cefaretti M, Mehta PT, Moore CL. Safety and efficacy of statins in patients with end-stage renal disease. Ann Pharmacother. 2013;47(10):1321–9.

    CAS  PubMed  Google Scholar 

  60. Horodinschi R-N, Stanescu AMA, Bratu OG, Pantea Stoian A, Radavoi DG, Diaconu CC. Treatment with statins in elderly patients. Medicina (Kaunas). 2019;55(11):721.

    PubMed  Google Scholar 

  61. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.

    Google Scholar 

  62. Kidney Disease: Improving Global Outcomes CKDMBDUWG. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1–59.

    Google Scholar 

  63. Tonelli M. Serum phosphorus in people with chronic kidney disease: you are what you eat. Kidney Int. 2013;84(5):871–3.

    CAS  PubMed  Google Scholar 

  64. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.

    PubMed  Google Scholar 

  65. Christodoulou M, Aspray TJ, Schoenmakers I. Vitamin D supplementation for patients with chronic kidney disease: a systematic review and meta-analyses of trials investigating the response to supplementation and an overview of guidelines. Calcified Tissue Int. 2021;109(2):157–78.

    CAS  Google Scholar 

  66. Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients. 2017;9(4):328.

    PubMed  PubMed Central  Google Scholar 

  67. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. J Am Geriatr Soc. 2014;62(1):147–52.

    Google Scholar 

  68. Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2016;27:367–76.

    CAS  PubMed  Google Scholar 

  69. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ (Clinical Research Ed). 2011;342:d2040.

    PubMed  Google Scholar 

  70. Moe SM. Calcium as a cardiovascular toxin in CKD-MBD. Bone. 2017;100:94–9.

    CAS  PubMed  Google Scholar 

  71. Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial. 2007;20(3):186–90.

    PubMed  Google Scholar 

  72. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.

    CAS  PubMed  Google Scholar 

  73. Nitta K, Yajima A, Tsuchiya K. Management of osteoporosis in chronic kidney disease. Intern Med. 2017;56(24):3271–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829–35.

    CAS  PubMed  Google Scholar 

  75. Gopaul A, Kanagalingam T, Thain J, Khan T, Cowan A, Sultan N, et al. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. 2021;16(1):1–9.

    Google Scholar 

  76. Bhanot RD, Kaur J, Bhat Z. Severe hypocalcemia and dramatic increase in parathyroid hormone after denosumab in a dialysis patient: a case report and review of the literature. Case Rep Nephrol. 2019;2019:3027419.

    PubMed  PubMed Central  Google Scholar 

  77. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19(7):1430–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions. EMA/84749/2014. Published on line 21 February 2014.

    Google Scholar 

  79. Ott SMJNRN. Therapy for patients with CKD and low bone mineral density. Nat Rev Nephrol. 2013;9(11):681–92.

    CAS  PubMed  Google Scholar 

  80. Sy J, Chen JLT, Kalantar-Zadeh K. New solutions to old problems-metabolic acidosis in chronic kidney disease. Ann Transl Med. 2020;8(19):1256.

    PubMed  PubMed Central  Google Scholar 

  81. Andrassy KM. Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int. 2013;84(3):622–3.

    CAS  PubMed  Google Scholar 

  82. Melamed ML, Raphael KL. Metabolic acidosis in CKD: a review of recent findings. Kidney Med. 2021;3(2):267–77.

    PubMed  PubMed Central  Google Scholar 

  83. Mannon EC, O’Connor PM. Alkali supplementation as a therapeutic in chronic kidney disease: what mediates protection? Am J Physiol-Renal Physiol. 2020;319(6):F1090–F104.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Di Iorio BR, Bellasi A, Raphael KL, Santoro D, Aucella F, Garofano L, et al. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol. 2019;32(6):989–1001.

    PubMed  PubMed Central  Google Scholar 

  85. Mathur RP, Dash SC, Gupta N, Prakash S, Saxena S, Bhowmik D. Effects of correction of metabolic acidosis on blood urea and bone metabolism in patients with mild to moderate chronic kidney disease: a prospective randomized single blind controlled trial. Renal Fail. 2006;28(1):1–5.

    CAS  Google Scholar 

  86. Bellasi A, Di Micco L, Santoro D, Marzocco S, De Simone E, Cozzolino M, et al. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease. BMC Nephrol. 2016;17(1):158.

    PubMed  PubMed Central  Google Scholar 

  87. Rizzetto F, Mafra D, Barra AB, Pires de Melo G, Abdalla DSP, Leite M Jr. One-year conservative care using sodium bicarbonate supplementation is associated with a decrease in electronegative LDL in chronic kidney disease patients: a pilot study. Cardiorenal Med. 2017;7(4):334–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Melamed ML, Horwitz EJ, Dobre MA, Abramowitz MK, Zhang L, Lo Y, et al. Effects of sodium bicarbonate in CKD stages 3 and 4: a randomized, placebo-controlled, multicenter clinical trial. Am J Kidney Dis. 2020;75(2):225–34.

    CAS  PubMed  Google Scholar 

  89. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant. 2009;24(4):1232–7.

    CAS  PubMed  Google Scholar 

  90. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne). 2021;8(328). [Review].

    Google Scholar 

  91. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24(3):495–9.

    CAS  PubMed  Google Scholar 

  92. Ratcliffe LE, Thomas W, Glen J, Padhi S, Pordes BA, Wonderling D, et al. Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis. 2016;67(4):548–58.

    PubMed  Google Scholar 

  93. National Clinical Guideline Centre (UK). National Institute for Health and Care Excellence: clinical guidelines. anaemia management in chronic kidney disease: partial Update 2015. London: Royal College of Physicians (UK); 2015.

    Google Scholar 

  94. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–55.

    CAS  PubMed  Google Scholar 

  95. Nolin TD, Himmelfarb J. Mechanisms of drug-induced nephrotoxicity. Handb Exp Pharmacol. 2010;196:111–30.

    CAS  Google Scholar 

  96. Fusco S, Garasto S, Corsonello A, Vena S, Mari V, Gareri P, et al. Medication-induced nephrotoxicity in older patients. Curr Drug Metab. 2016;17(6):608–25.

    CAS  PubMed  Google Scholar 

  97. Kohli HS, Bhaskaran MC, Muthukumar T, Thennarasu K, Sud K, Jha V, et al. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant. 2000;15(2):212–7.

    CAS  PubMed  Google Scholar 

  98. Groeneveld AB, Tran DD, van der Meulen J, Nauta JJ, Thijs LG. Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron. 1991;59(4):602–10.

    CAS  PubMed  Google Scholar 

  99. Zanardo G, Michielon P, Paccagnella A, Rosi P, Calo M, Salandin V, et al. Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors. J Thorac Cardiovasc Surg. 1994;107(6):1489–95.

    CAS  PubMed  Google Scholar 

  100. Vivino G, Antonelli M, Moro ML, Cottini F, Conti G, Bufi M, et al. Risk factors for acute renal failure in trauma patients. Intensive Care Med. 1998;24(8):808–14.

    CAS  PubMed  Google Scholar 

  101. Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant. 1999;14(5):1158–62.

    CAS  PubMed  Google Scholar 

  102. de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000;26(7):915–21.

    PubMed  Google Scholar 

  103. Bove T, Calabro MG, Landoni G, Aletti G, Marino G, Crescenzi G, et al. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth. 2004;18(4):442–5.

    PubMed  Google Scholar 

  104. Bahar I, Akgul A, Ozatik MA, Vural KM, Demirbag AE, Boran M, et al. Acute renal failure following open heart surgery: risk factors and prognosis. Perfusion. 2005;20(6):317–22.

    PubMed  Google Scholar 

  105. Landoni G, Bove T, Crivellari M, Poli D, Fochi O, Marchetti C, et al. Acute renal failure after isolated CABG surgery: six years of experience. Minerva Anestesiol. 2007;73(11):559–65.

    CAS  PubMed  Google Scholar 

  106. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med. 1998;128(3):194–203.

    CAS  PubMed  Google Scholar 

  107. Wen J, Cheng Q, Zhao J, Ma Q, Song T, Liu S, et al. Hospital-acquired acute kidney injury in Chinese very elderly persons. J Nephrol. 2013;26(3):572–9.

    PubMed  Google Scholar 

  108. Oliveira JF, Silva CA, Barbieri CD, Oliveira GM, Zanetta DM, Burdmann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53(7):2887–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Mendes CA, Cordeiro JA, Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother. 2009;43(12):1948–55.

    CAS  PubMed  Google Scholar 

  110. Wang X, Bonventre JV, Parrish AR. The aging kidney: increased susceptibility to nephrotoxicity. Int J Mol Sci. 2014;15(9):15358–76.

    PubMed  PubMed Central  Google Scholar 

  111. Li G, Lian X, Hao W, Hu W. Clinical characteristics and risk factors for mortality in older patients with dialysis-receiving community-acquired acute kidney injury. Int J Gen Med. 2021;14:5693–701.

    PubMed  PubMed Central  Google Scholar 

  112. Bagshaw SM. The long-term outcome after acute renal failure. Curr Opin Crit Care. 2006;12(6):561–6.

    PubMed  Google Scholar 

  113. Morgera S, Schneider M, Neumayer HH. Long-term outcomes after acute kidney injury. Crit Care Med. 2008;36(4 Suppl):S193–7.

    PubMed  Google Scholar 

  114. Coca SG. Acute kidney injury in elderly persons. Am J Kidney Dis. 2010;56(1):122–31.

    PubMed  PubMed Central  Google Scholar 

  115. Wu VC, Wu PC, Wu CH, Huang TM, Chang CH, Tsai PR, et al. The impact of acute kidney injury on the long-term risk of stroke. J Am Heart Assoc. 2014;3(4)

    Google Scholar 

  116. Eftekhari P. Evaluation of acute kidney injury in the hospital setting. Prim Care. 2014;41(4):779–802.

    PubMed  Google Scholar 

  117. Philips BJ, Lane K, Dixon J, Macphee I. The effects of acute renal failure on drug metabolism. Expert Opin Drug Metab Toxicol. 2014;10(1):11–23.

    CAS  PubMed  Google Scholar 

  118. Cox ZL, McCoy AB, Matheny ME, Bhave G, Peterson NB, Siew ED, et al. Adverse drug events during AKI and its recovery. Clin J Am Soc Nephrol. 2013;8(7):1070–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  119. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.

    Google Scholar 

  120. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008;37(6):673–9.

    PubMed  Google Scholar 

  121. Nawaz S, Cleveland T, Gaines PA, Chan P. Clinical risk associated with contrast angiography in metformin treated patients: a clinical review. Clin Radiol. 1998;53(5):342–4.

    CAS  PubMed  Google Scholar 

  122. Subramaniam RM, Wilson RF, Turban S, et al. AHRQ comparative effectiveness reviews. In: Contrast-induced nephropathy: comparative effectiveness of preventive measures. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016.

    Google Scholar 

  123. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim TH, et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury—a systematic review and meta-analysis. Circ J. 2012;76(9):2255–65.

    CAS  PubMed  Google Scholar 

  124. Markota D, Markota I, Starcevic B, Tomic M, Prskalo Z, Brizic I. Prevention of contrast-induced nephropathy with Na/K citrate. Eur Heart J. 2013;34(30):2362–7.

    CAS  PubMed  Google Scholar 

  125. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814–23.

    PubMed  Google Scholar 

  126. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol. 1999;33(2):403–11.

    CAS  PubMed  Google Scholar 

  127. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260–9.

    CAS  PubMed  Google Scholar 

  128. Investigators ACT. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250–9.

    Google Scholar 

  129. Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378(7):603–14.

    CAS  PubMed  Google Scholar 

  130. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63(1):71–9.

    CAS  PubMed  Google Scholar 

  131. Zhou X, Dai J, Xu X, Wang Z, Xu H, Chen J, et al. Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: a network meta-analysis. Angiology. 2019;70(4):305–16.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Luca Soraci .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Corsonello, A., Rocca, A., Russo, C.L., Soraci, L. (2023). Optimizing Pharmacotherapy in Older Patients: An Interdisciplinary Approach: Chronic Kidney Disease. In: Cherubini, A., Mangoni, A.A., O’Mahony, D., Petrovic, M. (eds) Optimizing Pharmacotherapy in Older Patients. Practical Issues in Geriatrics. Springer, Cham. https://doi.org/10.1007/978-3-031-28061-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-28061-0_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-28060-3

  • Online ISBN: 978-3-031-28061-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics